Impact of the new definitions in the prevalence of the metabolic syndrome in an adult population at Bucaramanga, Colombia
Keywords:
coronary disease, insulin resistance, obesity, diagnosis
Abstract
Introduction. The prevalence of metabolic syndrome depends on the criteria used for its classification. Three criteria in common use are those from International Diabetes Federation (IDF), the Adult Treatment Panel (ATP-III) or its update (ATP-IIIa).Objective. The prevalence statistic for generated for metabolic syndrome was compared for on the basis of each of the three criteria.
Materials and methods. The sample consisted of 155 teachers and employees in the school of medicine. The average age was 40.9; 54.2% were men. The three criteria were applied and the prevalences were compared with the Wilcoxon test and Cohen's kappa.
Results. Metabolic syndrome prevalence generated by each criterion was as follows: ATP-III was 12.3% (95%CI 7.5-18.5), ATP-IIIa was 34.8% (95%CI 27.4-42.9) and IDF 32.9% (95%CI 25.6--40.9). The prevalence indicated by ATP-III was lower than the ATP-IIIa or IDF prevalances (p < 0,001); however those of ATPIII-a and IDF were similar (p=0,083). Poor agreement was seen between ATP-III and ATP-IIIa (k=0.414, IC95% 0.409-0.420), and between ATP-III and IDF (k=0.374, IC95% 0.368-0.379); however, very good agreement was obtained between ATP-IIIa and IDF (k=0.957, IC95% 0.950-0.963).
Conclusion. The new definitions for metabolic syndrome, ATP-IIIa and IDF, increase the prevalence statistic by three times. This occurred despite the inclusion in IDF of an obesity factor in the criteria set.
Downloads
Download data is not yet available.
References
1. Bautista LE. Tendencias de la mortalidad por enfermedades cardiovasculares en Colombia y Santander, 1980-1996. Bucaramanga: Universidad Industrial de Santander, Organización Panamericana de
la Salud; 2000.
2. Cubillos-Garzón LA, Casas JP, Morillo CA, Bautista LE. Congestive heart failure in Latin America: the next epidemic. Am Heart J. 2004;147:412-7.
3. Pearson TA. Cardiovascular disease in developing countries: myths, realities, and opportunities. Cardiovasc Drugs Ther. 1999;13:95-104.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
5. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
6. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391-7.
7. Bautista LE, Morillo CA, Casas JP, Arenas IA, Ardila E. Estudio global de casos y controles para identificar factores de riesgo para infarto agudo del miocardio in diferentes poblaciones étnicas. INTERHEARTColombia. Reporte técnico. Bogotá D.C: Colciencias; 2002.
8. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkanen L, Selby J, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45:742-8.
9. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of Creactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:2016-21.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
11. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
12. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002; 18 (Suppl 3):S27-31.
13. Villegas A, Botero LF. Prevalencia de síndrome metabólico en la población de El Retiro. Rev ALAD. 2004;12:20.
14. Flórez H, Silva E, Fernández V, Ryder E, Sulbarán T, Campos G, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005;69:63-77.
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.
17. Pickering TG. For the American Society of Hypertension Ad Hoc Panel. Recommendations for the use of Home (Self) and Ambulatory Blood Pressure Monitoring. Am J Hypertens. 1996;9:1-12.
18. Marks GC, Habickt JP, Mueller WH. Reliability, dependability, and precision of anthropometric measurements, The Second National Health and Nutrition Examination Survey 1976-1980. Am J
Epidemiol. 1989;130:578-87.
19. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80-3.
20. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measur. 1960;20:37-46.
21. StataCorp. Stata statistical software: release 9,2. College Station: StataCorp LP; 2005.
22. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-304.
23. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
24. Karter AJ, D'Agostino RB Jr, Mayer-Davis EJ, Wagenknecht LE, Hanley AJ, Hamman RF, et al. Abdominal obesity predicts declining insulin sensitivity in nonobese diabetes. Obes Metabolism. 2005;7:230-8.
25. Perez M, Casas JP, Cubillos-Garzon LA, Serrano NC, Silva F, Morillo CA, et al. Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2003;10:328-35.
26. Lorenzo C, Serrano-Rios M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique JA, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003;11:1480-7.
27. Mendivil C, Sierra I, Pérez C. Valoración del riesgo cardiovascular global y prevalencia de dislipemias según los criterios del NCEP-ATPIII en una población adulta de Bogotá, Colombia. Clin Invest Arterioscl. 2004;16:99-107
28. Guerrero-Romero F, Rodríguez-Morán M. Concordance between the 2005 International Diabetes Federation Definition for Diagnosing Metabolic Syndrome With the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care. 2005;28:2588-9.
29. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-9.
30. Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chittleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome implications of the new International Diabetes Federation consensus definition. Diabetes Care. 2005;28:2777-9.
31. Carnethon MR, Loria CM, Hill JO, Sidney S, Savage P, Liu K. Risk factors for the metabolic syndrome: The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care. 2004;27:2707-15.
la Salud; 2000.
2. Cubillos-Garzón LA, Casas JP, Morillo CA, Bautista LE. Congestive heart failure in Latin America: the next epidemic. Am Heart J. 2004;147:412-7.
3. Pearson TA. Cardiovascular disease in developing countries: myths, realities, and opportunities. Cardiovasc Drugs Ther. 1999;13:95-104.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
5. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
6. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391-7.
7. Bautista LE, Morillo CA, Casas JP, Arenas IA, Ardila E. Estudio global de casos y controles para identificar factores de riesgo para infarto agudo del miocardio in diferentes poblaciones étnicas. INTERHEARTColombia. Reporte técnico. Bogotá D.C: Colciencias; 2002.
8. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkanen L, Selby J, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45:742-8.
9. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of Creactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:2016-21.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
11. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
12. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002; 18 (Suppl 3):S27-31.
13. Villegas A, Botero LF. Prevalencia de síndrome metabólico en la población de El Retiro. Rev ALAD. 2004;12:20.
14. Flórez H, Silva E, Fernández V, Ryder E, Sulbarán T, Campos G, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005;69:63-77.
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.
17. Pickering TG. For the American Society of Hypertension Ad Hoc Panel. Recommendations for the use of Home (Self) and Ambulatory Blood Pressure Monitoring. Am J Hypertens. 1996;9:1-12.
18. Marks GC, Habickt JP, Mueller WH. Reliability, dependability, and precision of anthropometric measurements, The Second National Health and Nutrition Examination Survey 1976-1980. Am J
Epidemiol. 1989;130:578-87.
19. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80-3.
20. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measur. 1960;20:37-46.
21. StataCorp. Stata statistical software: release 9,2. College Station: StataCorp LP; 2005.
22. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-304.
23. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
24. Karter AJ, D'Agostino RB Jr, Mayer-Davis EJ, Wagenknecht LE, Hanley AJ, Hamman RF, et al. Abdominal obesity predicts declining insulin sensitivity in nonobese diabetes. Obes Metabolism. 2005;7:230-8.
25. Perez M, Casas JP, Cubillos-Garzon LA, Serrano NC, Silva F, Morillo CA, et al. Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2003;10:328-35.
26. Lorenzo C, Serrano-Rios M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique JA, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003;11:1480-7.
27. Mendivil C, Sierra I, Pérez C. Valoración del riesgo cardiovascular global y prevalencia de dislipemias según los criterios del NCEP-ATPIII en una población adulta de Bogotá, Colombia. Clin Invest Arterioscl. 2004;16:99-107
28. Guerrero-Romero F, Rodríguez-Morán M. Concordance between the 2005 International Diabetes Federation Definition for Diagnosing Metabolic Syndrome With the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care. 2005;28:2588-9.
29. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-9.
30. Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chittleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome implications of the new International Diabetes Federation consensus definition. Diabetes Care. 2005;28:2777-9.
31. Carnethon MR, Loria CM, Hill JO, Sidney S, Savage P, Liu K. Risk factors for the metabolic syndrome: The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care. 2004;27:2707-15.
How to Cite
1.
Pinzón JB, Serrano NC, Díaz LA, Mantilla G, Velasco HM, Martínez LX, et al. Impact of the new definitions in the prevalence of the metabolic syndrome in an adult population at Bucaramanga, Colombia. biomedica [Internet]. 2007 Jun. 1 [cited 2024 May 19];27(2):172-9. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/213
Some similar items:
- Liliana Franco-Hincapié, Constanza Elena Duque, María Victoria Parra, Natalia Gallego, Alberto Villegas, Andrés Ruiz-Linares, Gabriel Bedoya, Association between polymorphism in uncoupling proteins and type 2 diabetes in a northwestern Colombian population , Biomedica: Vol. 29 No. 1 (2009)
- Alicia Norma Alayón, Ana Patricia Rivadeneira, Carlos Herrera, Heidy Guzmán, Dioneris Arellano, Isabella Echeverri, Metabolic and inflammatory postprandial effect of a highly saturated fat meal and its relationship to abdominal obesity , Biomedica: Vol. 38 No. Sup.1 (2018): Suplemento 1, Enfermedades crónicas
- Edwin Abraham Medina, Middle ear adenoma , Biomedica: Vol. 29 No. 3 (2009)
- Alberto Tobón, Danger signs in the malaria patient , Biomedica: Vol. 29 No. 2 (2009)
- Elpidia Poveda, Diana Giraldo, Yibby Forero, Carlos Mendivil, Self-reported physical activity in comparison with anthropometric body fat indicators in school children , Biomedica: Vol. 28 No. 3 (2008)
- Leandro Galvis, Ángel Y. Sánchez, Leonardo F. Jurado, Martha I. Murcia, Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia , Biomedica: Vol. 38 No. 1 (2018)
- Oscar Fernando Herrán, María F. Ardila, Categories of alcohol consumers and the criteria for classification , Biomedica: Vol. 29 No. 4 (2009)
- María Imaz, Sonia Allassia, Mónica Aranibar, Alba Gunia, Susana Poggi, Ana Togneri, Lidia Wolff, Group of Implementation of Fluorescence, Performance of LED fluorescence microscopy for the detection of acid-fast bacilli from respiratory samples in peripheral laboratories in Argentina , Biomedica: Vol. 37 No. 2 (2017)
- Claudia Llerena, Santiago Elías Fadul, María Consuelo Garzón, Graciela Mejía, Dora Leticia Orjuela, Luz Mary García, Hilda Beatriz Álvarez, Fernando Javier Ruiz, Drug-resistant Mycobacterium tuberculosis in children under 15 years , Biomedica: Vol. 30 No. 3 (2010)
- Nora Elena Múnera, Rosa Magdalena Uscátegui, Beatriz Elena Parra, Luz Mariela Manjarrés, Fredy Patiño, Claudia María Velásquez, Alejandro Estrada, Gabriel Bedoya, Vicky Parra, Angélica María Muñoz, Ana Carolina Orozco, Gloria María Agudelo, Environmental risk factors and metabolic syndrome components in overweight youngsters , Biomedica: Vol. 32 No. 1 (2012)
Issue
Section
Original articles
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
